<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720483</url>
  </required_header>
  <id_info>
    <org_study_id>17-1477</org_study_id>
    <nct_id>NCT03720483</nct_id>
  </id_info>
  <brief_title>Inhaled NAC in Treatment of IPF</brief_title>
  <official_title>Pilot Study to Evaluate Inhaled N-Acetylcysteine in Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine&#xD;
      (NAC) in patients with pulmonary fibrosis. The study will also create a bank of data, blood,&#xD;
      and sputum from IPF patients for future research.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine&#xD;
      (NAC) in patients with pulmonary fibrosis. The study will also create a bank of data, blood,&#xD;
      and sputum from IPF patients for future research.&#xD;
&#xD;
      NAC is a medication used to loosen thick mucus. NAC was initially licensed for use in 1968.&#xD;
      It is on the World Health Organization's List of Essential Medicines, the most effective and&#xD;
      safe medicines needed in a health system, and it is available as a generic medication and is&#xD;
      not very expensive. Inhaled NAC has been used as a mucus-dissolving therapy in respiratory&#xD;
      conditions with excessive and/or thick mucus production.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study encountered challenges during startup due to the COVID-19 epidemic and was withdrawn.&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Pulmonary function - FVC</measure>
    <time_frame>Baseline, week 10, and week 18</time_frame>
    <description>Measure changes in percent predicted FVC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Pulmonary function - DLCO</measure>
    <time_frame>Baseline, week 10, and week 18</time_frame>
    <description>Measure changes in percent predicted DLCO</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis (IPF)</condition>
  <arm_group>
    <arm_group_label>N-acetyl cysteine then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive NAC followed by placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then N-acetyl cysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive placebo followed by NAC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl cysteine then Placebo</intervention_name>
    <description>Subject will receive N-acetyl cysteine first followed by Placebo</description>
    <arm_group_label>N-acetyl cysteine then placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo then N-acetyl cysteine</intervention_name>
    <description>Subject will receive Placebo first followed by N-acetyl cysteine</description>
    <arm_group_label>Placebo then N-acetyl cysteine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed by study team with expertise in IPF utilizing standard ATS/ERS definition of&#xD;
             &quot;probable&quot; or &quot;definite&quot; IPF&#xD;
&#xD;
          -  DLCO &gt;50% predicted&#xD;
&#xD;
          -  FVC &gt;60% predicted&#xD;
&#xD;
          -  FEV1/FVC &gt; 0.7&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of bronchospasm (requiring treatment)&#xD;
&#xD;
          -  Current acute exacerbation of their IPF disease&#xD;
&#xD;
          -  Current smoker&#xD;
&#xD;
          -  Supplemental O2 requirement &gt; 4 liters/min via nasal cannula&#xD;
&#xD;
          -  History of asthma, COPD, coronary artery disease, or cancer&#xD;
&#xD;
          -  Currently using NAC, hypertonic saline, or DNase (dornase alfa) inhalation therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Steele, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

